心肌梗塞治療藥物市場規模、佔有率、成長分析，按治療類型、藥物類別、給藥途徑、最終用戶、地區 - 產業預測，2025-2032

2023年全球心肌梗塞（MI）治療市場規模估值為217.5億美元，從2024年的227.3億美元成長到2032年的323.2億美元，在預測期內（2025年）預計複合年成長率為2032 年為4.5%）。

心肌梗塞（MI）治療市場預計將顯著成長，這主要是由於冠狀動脈疾病（心臟病發作的主要原因）盛行率不斷上升。每年約有 1730 萬人死於心臟病，因此尋找有效治療方案的迫切性從未如此迫切。人口老化、肥胖率上升以及糖尿病和高血壓等慢性疾病等因素導致了這一成長。此外，不良飲食習慣和濫用藥物等生活方式選擇也會增加心肌梗塞的風險。此外，技術進步帶來了精確閉塞檢測和個人化治療方法的創新方法，也正在推動市場發展。隨著有效治療方法的推廣，心肌梗塞治療市場預計將擴大，為相關人員創造利潤豐厚的機會。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術分析
• 監管分析
• 專利分析
• 案例研究

全球心肌梗塞（MI）治療市場規模及依治療類型分類的複合年成長率（2025-2032）

• 市場概況
• 溶栓
  • 鏈球菌激酶
  • 重組組織胞漿素原原活化劑 (rtPA)
• 經皮皮冠狀動脈介入治療（PCI）
  • 球囊血管成形術
  • 支架置入術（藥物釋放型支架裸金屬支架）
• 冠狀動脈繞道手術手術（CABG）
• 藥物（手術或介入治療之前或之後使用）
• 其他新治療方法

全球心肌梗塞（MI）治療市場規模及依藥物類別分類的複合年成長率（2025-2032）

• 市場概況
• 抗血小板藥
• 抗凝血物
• BETA受體阻斷劑
• 他汀類藥物（降膽固醇藥物）
• Atorvastatin
• 其他

全球心肌梗塞 (MI) 治療市場規模及依給藥途徑分類的複合年成長率 (2025-2032)

• 市場概況
• 口服
• 錠劑
• 膠囊
• 注射
• 靜脈注射 (IV)
• 皮下注射（SC）
• 經皮的
• 修補

全球心肌梗塞 (MI) 治療市場規模及最終用戶複合年成長率（2025-2032）

• 市場概況
• 醫院
• 專科診所
• 日間手術中心 (ASC)
• 居家醫療

全球心肌梗塞（MI）治療市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
• 產品系列分析
• 按細分市場分類的佔有率分析
• 收益與前一年同期比較（2022-2024）

  主要企業簡介

  • 阿斯特捷利康公司（英國）
  • 勃林格殷格翰國際有限公司（德國）
  • 禮來公司（美國）
  • 安進（美國）
  • 諾華公司（瑞士）
  • Idorsia 製藥有限公司（瑞士）
  • 法拉第製藥（美國）
  • 立即治療（美國）
  • 三菱化學集團（日本）
  • 坎塞拉（瑞典）
  • 拜耳公司（德國）
  • 雷卡迪奧（美國）
  • Mesoblast 有限公司（澳洲）
  • Athera BIOTechnologies AB（瑞典）
  • 百時美施貴寶公司（美國）
  • CeleCor Therapeutics（美國）
  • CHIESI Farmaceutici SpA（義大利）
  • CSL 有限公司（澳洲）
  • 永至生技（台灣）

結論和建議

Global Myocardial Infarction (MI) Therapeutics Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.73 billion in 2024 to USD 32.32 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The Myocardial Infarction (MI) Therapeutics Market is poised for significant growth, primarily driven by the rising incidence of coronary artery disease, the leading cause of heart attacks. With approximately 17.3 million global fatalities attributed to heart disease annually, the urgency for effective treatment options has never been higher. Factors such as an aging population, increasing rates of obesity, and chronic conditions like diabetes and hypertension are contributing to this uptick. Additionally, lifestyle choices, including poor diet and substance abuse, are escalating myocardial infarction risk. The market is further bolstered by advancements in technology, promising innovative methods for precise blockage detection and personalized treatment approaches. As effective therapies gain traction, the MI treatment market is expected to expand, presenting lucrative opportunities for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Myocardial Infarction (MI) Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Myocardial Infarction (MI) Therapeutics Market Segmental Analysis

Global Myocardial Infarction (MI) Therapeutics Market is segmented by Therapy Type, Drug Class, Route of Administration, End-User and region. Based on Therapy Type, the market is segmented into Thrombolysis, Primary Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications (used before or after surgery or intervention therapy) and Other Emerging Therapies. Based on Drug Class, the market is segmented into Antiplatelet Agents, Anticoagulants, Beta-Blockers, Statins (Cholesterol-Lowering Drugs), Atorvastatin and Others. Based on Route of Administration, the market is segmented into Oral, Tablets, Capsules, Injectable, Intravenous (IV), Subcutaneous (SC), Transdermal and Patches. Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs) and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Myocardial Infarction (MI) Therapeutics Market

The global Myocardial Infarction (MI) Therapeutics Market is expected to experience significant growth due to the increasing prevalence of heart attacks worldwide. Key factors contributing to this growth include the rising rates of coronary artery disease and lifestyle changes, which are leading to more cases of MI. Over the upcoming years, a surge in hypertension, obesity, and smoking prevalence is likely to further stimulate demand for myocardial infarction therapies. As healthcare systems adapt to address these challenges, the market is anticipated to expand, reflecting the growing need for effective treatments and interventions to manage this critical health issue.

Restraints in the Global Myocardial Infarction (MI) Therapeutics Market

The global Myocardial Infarction (MI) Therapeutics Market faces several significant constraints that may impede its growth in the coming years. Chief among these are the escalating costs associated with research and development, alongside limitations in R&D activities. Additionally, rising overall healthcare expenditures, stringent regulatory requirements, and the substantial financial investments needed for clinical trials further compound these challenges. These factors collectively create a challenging environment for companies aiming to innovate and develop effective treatments for myocardial infarction, potentially stunting market expansion and advancements in therapeutic options for patients.

Market Trends of the Global Myocardial Infarction (MI) Therapeutics Market

The Global Myocardial Infarction (MI) Therapeutics Market is increasingly influenced by the integration of nanoparticle technology, facilitating targeted drug delivery and advanced imaging techniques for cardiovascular diseases. Recent innovations in nanoparticle design and functionality are enhancing preclinical research, enabling efficient therapeutic mechanisms that address critical challenges such as low bioavailability and bioimaging inefficiencies. By focusing on specific actions against inflammation, fibrogenesis, and promoting angiogenesis, the development of nanocarrier systems is poised to revolutionize MI treatment. This trend reflects a significant shift toward precision medicine, presenting opportunities for more effective solutions in MI diagnostics and therapeutics, thus shaping the future landscape of cardiovascular care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Myocardial Infarction (MI) Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Thrombolysis
  • Streptokinase
  • Recombinant Tissue Plasminogen Activator (rtPA)
• Primary Percutaneous Coronary Intervention (PCI)
  • Balloon Angioplasty
  • Stenting (Drug-Eluting Stents, Bare-Metal Stents)
• Coronary Artery Bypass Grafting (CABG)
• Medications (used before or after surgery or intervention therapy)
• Other Emerging Therapies

Global Myocardial Infarction (MI) Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antiplatelet Agents
• Anticoagulants
• Beta-Blockers
• Statins (Cholesterol-Lowering Drugs)
• Atorvastatin
• Others

Global Myocardial Infarction (MI) Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Tablets
• Capsules
• Injectable
• Intravenous (IV)
• Subcutaneous (SC)
• Transdermal
• Patches

Global Myocardial Infarction (MI) Therapeutics Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

Global Myocardial Infarction (MI) Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Type, Drug Class, Route of Administration, End-User)
  • US
  • Canada
• Europe (Therapy Type, Drug Class, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Drug Class, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Drug Class, Route of Administration, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Drug Class, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Pharmaceuticals Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faraday Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immediate Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Chemical Group (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kancera (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recardio (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athera Biotechnologies AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CeleCor Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CHIESI Farmaceutici SpA (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ever Supreme Bio Technology (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations